{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-020508","form_type":"8-K","ticker":"KURA","cik":"0001422143","company_name":"Kura Oncology, Inc.","filed_at":"2023-05-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:38.799446+00:00","generated_at":"2026-06-15T06:08:41.139441+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Kura Oncology Q1 net loss $34.1M; ziftomenib enrollment outperforming projections","bullets":["Net loss $34.1M vs $32.5M YoY; R&D expense $25.2M; cash $405.9M provides runway into Q4 2025.","Phase 2 registration trial of ziftomenib in NPM1-mutant AML enrollment exceeding initial projections; 85-patient target.","Updated Phase 1 ziftomenib data to be presented at EHA June 2023; 6/20 NPM1-mutant patients achieved CR at RP2D.","FDA cleared IND for KO-2806, a next-generation FTI; FIT-001 Phase 1 trial expected to dose first patients H2 2023.","First combination study KOMET-007 (ziftomenib + standards of care) to dose first patients in Q2 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-020508","json":"https://secwatch.observer/filing/0000950170-23-020508.json","markdown":"https://secwatch.observer/filing/0000950170-23-020508.md","text":"https://secwatch.observer/filing/0000950170-23-020508.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1422143/000095017023020508/0000950170-23-020508-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1422143/000095017023020508/kura-20230510.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T06:08:41.139441+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0962c09b75c508d2a6b3f3071acbefa5b6a6c1f2","claim":"Kura Oncology, Inc. reported first quarter ended March 31, 2023 results: net income $34.1 million.","evidence_excerpt":"Net loss for the first quarter of 2023 was $34.1 million","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1422143/000095017023020508/0000950170-23-020508-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2023"},{"label":"Net income","value":"$34.1 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}